Skip to main content
. 2021 Jul 9;3(3):zcab027. doi: 10.1093/narcan/zcab027

Figure 2.

Figure 2.

Gene expression analysis of publicly available datasets. (A) Correlation of ESR1 with ZEB1, SNAI2 (SLUG) and activity of MSigDB Hallmark EMT signature (ssGSEA scores) in a cohort of 87 ER+ breast cancer patients (GSE6532). (B) Correlation of tamoxifen resistance (ssGSEA scores) signature with expression of ZEB1 and SNAI2 and activity of hallmark EMT signature in primary breast tumors treated with tamoxifen in adjuvant setting (GSE9195). (C) Correlation of ESR1 expression levels and estrogen response activity with CDH1 and VIM in tumor samples from 298 ER+ patients treated with tamoxifen for 5 years. (D) Diagonal correlation matrix between expression levels (ZEB1, SLUG, VIM, CDH1, ESR1), EMT scoring metrics (76GS, MLR and KS) and gene set activity estimation (ER early response, ER late response, tamoxifen resistance, hallmark EMT signatures) for 60 samples of micro-dissected tumour biopsies (GSE1378) and whole tissue tumour biopsies (GSE1379) from a cohort of patients treated with tamoxifen for 5 years. (E) Correlation plots of estimated activities of estrogen response with hallmark EMT signatures in different subtypes of breast cancer in TCGA. Spearman correlation coefficient (ρ) and corresponding P-value are reported.